



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
WASHINGTON, D.C. 20460

MAR 7 1995

OFFICE OF  
PREVENTION, PESTICIDES AND  
TOXIC SUBSTANCES

Subject: Imazalil, Quantitative Risk Assessment, Two-Year  
Charles River SPF Swiss Albino Mouse Dietary  
Study

Caswell No. 497B

From: Bernice Fisher, Biostatistician  
Statistics Section  
Science Analysis Branch/HED (7509C)

*Bernice Fisher*  
3/7/95

To: Henry W. Spencer, Ph.D., Pharmacologist  
Review Section III  
Toxicology Branch I/HED (7509C)

Thru: Hugh M. Pettigrew, PhD, Section Head  
Statistics Section  
Science Analysis Branch/HED (7509C)

*Hugh M. Pettigrew*  
3/7/95

Summary

The estimated unit risk,  $Q_1$  (mg/kg/day)<sup>-1</sup> of Imazalil, based upon the male mouse hepatocellular (adenomas, and/or carcinomas) tumors is  $6.20 \times 10^{-2}$  in human equivalents (converted from animals to humans by use of the 3/4's scaling factor-1994, Tox\_Risk, 3.5-K.Crump)<sup>\*</sup>. The dose levels used in the 100 week study were 0, 50, 200, and 600 ppm of Imazalil. The corresponding tumor rates for the male mice were 10/50, 8/47, 17/50, and 22/48 respectively.

\* See Memo - Deriving  $Q_1$ 's Using the Unified Interspecies Scaling Factors, P.A. Fenner-Crisp, Director-HED, 7/1/94.

cc: Caswell file  
B.Doyle  
D.Edwards

K.Baetcke  
K.Hamernik

①



Recycled/Recyclable  
Printed with Soy/Canola Ink on paper that  
contains at least 50% recycled fiber

## Background

In August, 1994, the Carcinogenicity Peer Review Committee recommended that a quantitative risk assessment for Imazalil be estimated from male mouse liver (adenomas and/or carcinomas) tumor rates.

The statistical evaluation (Imazalil Qualitative Risk Assessment Based on Charles River SPF Swiss Albino Mouse Dietary Study, L.Brunsmann 7/94) indicated no significant dose related differential mortality in the male mice.

Male mice had a dose related significant ( $p < .01$ ) increasing trend in hepatocellular (adenomas and/or carcinomas) tumor rates and also a significant difference in the pair-wise comparison of the 600 ppm dose group and the controls.

## Dose-Response

Since mortality was not affected differentially with increasing doses of Imazalil, the estimate of the unit risk,  $Q_1^*$ , in human equivalents was obtained by the application of the Multi-Stage model (Tox\_Risk program, version 3.5 - K.Crump). An estimate of the risk was calculated from male mouse hepatocellular (adenomas and/or carcinomas) tumor rates.

The resulting estimates of unit risk,  $Q_1^*$ , were converted to human equivalents by the use of weights of .03 kg for the mice and 70 kg for humans and the  $3/4$ 's scaling factor for interspecies extrapolation.

It is to be noted that  $Q_1^*$  ( $\text{mg/kg/day}$ )<sup>-1</sup> is an estimate of the upper bound on risk and that (as stated in the EPA Risk Assessment Guidelines) "the true value of the risk is unknown, and may be as low as zero."

2